Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537727 | 1.00 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL6510567 | 1.00 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL1685053 | 1.00 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL30725710 | 1.00 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL10490497 | 1.00 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL10490370 | 1.00 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL30725711 | 1.00 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL120065 | 0.95 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL115968 | 0.95 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 | |
| SCHEMBL116743 | 0.95 | KMT2A (0.64) | KMT2AMAPTDNM1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034081-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2025-01-30 | — | — | US | disclosed |
| US-11634379-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-04-25 | — | — | US | disclosed |
| EP-4148083-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| EP-3766916-B1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2022-09-28 | — | — | EP | disclosed |
| US-20210107861-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2021-04-15 | — | — | US | disclosed |
| EP-3766916-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2021-01-20 | — | — | EP | disclosed |
| EP-3160938-B1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2020-09-16 | — | — | EP | disclosed |
| US-10723692-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2020-07-28 | — | — | US | disclosed |
| US-20190270697-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2019-09-05 | — | — | US | disclosed |
| US-10106490-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2018-10-23 | — | — | US | disclosed |
| US-20170283367-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2017-10-05 | — | — | US | disclosed |
| US-9737619-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2017-08-22 | — | — | US | disclosed |
| US-9738593-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | ACUITAS THERAPEUTICS INC. (CA) | 2017-08-22 | — | — | US | disclosed |
| US-20170157268-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2017-06-08 | — | — | US | disclosed |
| EP-3160938-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2017-05-03 | — | — | EP | disclosed |
| US-20150376115-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| WO-2015199952-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC. (CA) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634379-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | APOB, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1469/4885MAPT 31/4885DNM1 1590/4885 |
| US-20170283367-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1521/4885MAPT 29/4885DNM1 1356/4885 |
| US-10106490-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | APOB, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1469/4885MAPT 31/4885DNM1 1590/4885 |
| US-20250034081-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1521/4885MAPT 29/4885DNM1 1356/4885 |
| US-20190270697-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1521/4885MAPT 29/4885DNM1 1356/4885 |
| US-20210107861-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | APOB, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1469/4885MAPT 31/4885DNM1 1590/4885 |
| US-20170157268-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1521/4885MAPT 29/4885DNM1 1356/4885 |
| US-10723692-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | APOB, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1469/4885MAPT 31/4885DNM1 1590/4885 |
| US-20150376115-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1521/4885MAPT 29/4885DNM1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.